Nateglinide incubation reduced protein content relative to muscle weight in flexor digitorum brevis (FDB) muscles. A reduction was also observed in soleus (SOL) muscles incubated with Nateglinide. [1]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Nateglinide effects on flexor digitorum brevis muscle protein content
Cell-based study · flexor digitorum brevis (FDB) [1]
Flexor digitorum brevis (FDB) muscles incubated with Nateglinide showed reduced protein content relative to muscle weight.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10−7 to 5 × 10−4 mol/L
- Exposure duration
- 24 h
- Method
- incubated
- Vehicle
- dimethyl sulfoxide (DMSO)
Methods and source locations
Compound reported in the paper: Nateglinide
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Drugs and solutions (S8); Materials and Methods > Drug-dependent atrophy in different skeletal muscle phenotypes of mice (S28); Figure 2 legend (S179, S180); Table 1 legend (S229); Table 1 (T1.h1, T1.r17, T1.r18)
percent reduction in the protein content/muscle weight: percent reduction in the protein content/muscle weight; comparator: corresponding contralateral muscles from the same animal incubated with DMEM+ solution alone — Figure 2 legend (S179); Table 1 (T1.h1, T1.r17, T1.r18)
Nateglinide effects on soleus muscle protein content
Cell-based study · soleus (SOL) [1]
Soleus (SOL) muscles incubated with Nateglinide showed reduced protein content relative to muscle weight.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10−7 to 5 × 10−4 mol/L
- Exposure duration
- 24 h
- Method
- incubated
- Vehicle
- dimethyl sulfoxide (DMSO)
Methods and source locations
Compound reported in the paper: Nateglinide
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Drugs and solutions (S8); Materials and Methods > Drug-dependent atrophy in different skeletal muscle phenotypes of mice (S28); Figure 2 legend (S179, S180); Table 1 legend (S229); Table 1 (T1.h1, T1.r17, T1.r20)
percent reduction in the protein content/muscle weight: percent reduction in the protein content/muscle weight; comparator: corresponding contralateral muscles from the same animal incubated with DMEM+ solution alone — Figure 2 legend (S179); Table 1 (T1.h1, T1.r17, T1.r20)
